View All Jobs
Our business is your health

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008.In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection. In 2015, we launched PRALUENT® (alirocumab) Injection, the first PCSK9 inhibitor in the U.S.


PRALUENT® (alirocumab) Injection EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept)


At Regeneron, we are committed to a better future. This promise is at the core of our mission to discover and develop new medicines, which allows us to deliver greater value to our patients, employees and communities.


Regeneron was founded by physician scientists, and today, more than 20 years later, strong science remains at the heart of our capabilities and culture.

Through our original research we have discovered novel drug targets such as angiopoietins and neurotrophins, and we have developed product candidates to these targets as well as to others that have been validated by academic researchers or other pharmaceutical companies.We have pursued both novel and validated targets because we believe this is a strategy that balances risk and reward.